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Microalbuminuria is associated with cardiovascular disease (CVD) mortality but whether 
lower levels of urine albumin excretion similarly predict CVD is uncertain. We investigated 
associations between urine albumin:creatinine ratio (UACR) <30mg/g, and incident 
hypertension, incident diabetes, all cause and CVD mortality, during a maximum of 11 years 
of follow-up. 
Methods and Results 
37,091 individuals in a health screening program between 2002 and 2012 with baseline 
measurements of urine albumin creatinine ratio (UACR) were studied. Cox proportional 
hazards models were used to estimate hazard ratios (HRs and 95% confidence intervals for 
incident hypertension, incident diabetes and mortality outcomes (lowest UACR quartile as 
reference) at follow-up. For linear risk trends, the quartile rank was used as a continuous 
variable in regression models. 
963 cases of incident hypertension, 511 cases of incident diabetes and 349 deaths occurred 
during follow-up. In the fully adjusted models, there was a significant HR for the association 
between UACR and incident hypertension [highest UACR quartile HR 1.95 (95%CI 
1.51,2.53), p value for trend across UACR quartiles p<0.001]. In contrast, the association 
between UACR and incident diabetes was not significant [highest UACR quartile, HR 1.15 
(95%CI 0.79,1.66), p value for trend p=0.20]. For CVD mortality, with increasing UACR 
quartiles, there was a significant increase in HR across quartiles, p=0.029, (for all cause 
mortality, p=0.078). 
Conclusions 
 Low levels of albuminuria, UACR below 30mg/g, is associated with increased risk of 
incident hypertension and CVD mortality at follow-up, but is not associated with increased 
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Chronic kidney disease (CKD) is a costly disease, and the costs associated with the care of 
patients with end-stage renal disease (ESRD) are estimated to exceed US$1 trillion 
globally.1 Albuminuria or microalbuminuria, albumin excretion rate (AER)≥30 mg/24 hours or 
albumin/creatinine ratio (ACR) ≥30 mg/g (≥3 mg/mmol)), is used as a marker of renal 
damage and used to define CKD along with low eGFR.2 Albuminuria is not only a predictor 
of development and progression of diabetic3 and non-diabetic4 renal diseases, but is a 
marker of endothelial dysfunction.5 In 1969, Keen and colleagues first showed that increased 
urinary albumin excretion (microalbuminuria) occurred in people with type 2 diabetes 
compared with controls occurred during an oral glucose tolerance test.6  
 
A recent meta-analyses based on more than one hundred thousand individuals with ACR 
data and 1.1 million participants with dipstick data from 21 general population cohorts 
demonstrated that albuminuria was associated with all-cause and cardiovascular mortality 
independently of each other and traditional cardiovascular risk factors.7 These data from 21 
studies from 14 countries of Asia, Europe, North America, and Oceania, showed consistency 
in both continuous and categorical models for ACR across the different regional cohorts. 
 
Both CVD and diabetes share many risk factors in common (the common soil hypothesis8) 
but whether UACR below 30mg/g similarly predicts mortality outcomes, hypertension and 
diabetes in the same population is uncertain. It is well established that microalbuminuria is 
associated with all cause and cardiovascular mortality, and microalbuminuria is associated 
with diabetes9 and resistant hypertension.10 However, although it has been shown that 
urinary albumin excretion predicts blood pressure progression in people without diabetes or 
hypertension, at levels of UACR below 30mg/g,9 it is less certain whether this levels are 



































































The aim of the study was to test the hypothesis that UACR below 30mg/g was associated 
with the following outcomes: incident hypertension, incident diabetes, and all cause and 
CVD mortality during a maximum of 11 years of follow up, in a middle aged relatively healthy 




































































The study population consisted of individuals who participated in a comprehensive health 
screening program with urine ACR(albumin creatinine ratio) at Kangbuk Samsung Hospital, 
Seoul, Korea from 2002 to 2012 (N=44,964). The purpose of the screening program was to 
promote health through early detection of chronic diseases and their risk factors. 
Additionally, the Korean Industrial Safety and Health Law demands working individual  
participate in an annual or biennial health examination. Participants were employees or 
spouses of companies or local governmental organizations who registered individually for 
the program. For this analysis, we opportunistically investigated associations between low 
levels of albuminuria, (below the threshold for defining microalbuminuria), and risks of 
incident hypertension, incident diabetes and CVD mortality at follow-up. Incident 
hypertension was defined by the presence of new antihypertensive medication, self reporting 
by the patient of hypertension, a blood pressure at follow up ≥140/90 mm Hg; incident 
diabetes was defined by new anti-diabetic medication, self reporting by the patient of 
diabetes or a fasting glucose at follow up ≥126mg/dL. Subjects were excluded for one or 
more of the following reasons: UACR ≥30mg/g, subjects with missing data for smoking, 
alcohol or exercise at baseline; subjects with a history of cancer; subjects with unknown 
mortality status. The total number of eligible subjects for testing associations with all cause 
and CVD mortality was 37,091 (Median FU: 5.13 years and mean (SD) FU: 4.99(2.57) 
years). To test the effect of low grade albuminuria for incident type 2 diabetes and 
hypertension, we studied 13,475 subjects who had baseline urine ACR and follow up data 
on more than one occasion between 2002 and 2013. To analyze associations between 
UACR and incident hypertension we additionally excluded; subjects with missing data for 
smoking, alcohol or exercise at baseline; subjects with hypertension at baseline and thus the 
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mean (SD) FU: 3,52(2.13)years). For testing associations between UACR and incident 
diabetes, data were available on 10,930 subjects (Median FU: 2.98 years and mean (SD) FU: 
3,47(2.17)) years after excluding subjects for missing data and subjects with type 2 diabetes 
at baseline. 
This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital. 




As part of the health screening program, individuals completed questionnaires related to 
their medical and social history and medication use. Individuals were asked about duration 
of education (years), frequency of exercise (none, less than once a week, at least once a 
week, ≥3 times per week (regular exercise)), smoking history (never, former, or current) and 
alcohol consumption (grams (g)/week). 
 
Trained staff also collected anthropom tric measurements and vital statistics. Body weight 
was measured in light clothing with no shoes to the nearest 0.1 kilogram using a digital scale. 
Height was measured to the nearest 0.1 centimeter. Body mass index (BMI) was calculated 
as weight in kilograms divided by height in meters squared. Blood pressure was measured 
using standard mercury sphygmomanometers. Blood samples were collected after at least 
10-hours of fasting and analyzed in the same core clinical laboratory. The core clinical 
laboratory has been accredited and participates annually in inspections and surveys by the 
Korean Association of Quality Assurance for Clinical Laboratories. 
 
Urinary albumin excretion was measured from an early morning urine sample as the urinary 
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immunoradiometry (radioimmunological competition assay; Immunotech), and 
immunoturbidimetric assay (Roche Modular P800), and urinary creatinine concentration was 
measured by a modified Jaffe method. The UACR measured in a spot urine sample is highly 
correlated with the 24-hour urine albumin excretion.11 All subjects with a UACR ≥30 mg/g 
were excluded from these analyses. 
Ascertainment of mortality 
Deaths among participants were identified by matching the information to death records from 
the National Statistical Office using identification numbers assigned to subjects at birth. 
Causes of death were coded centrally by trained coders using the ICD-10 classification 
(International Classification of Diseases, 10th revision) and ICD 00-99 was considered to 
represent cardiovascular death. 
 
Statistical analyses  
The statistical analysis was performed using STATA version 11.2 (StataCorp LP, College 
Station, TX, USA). Reported P values were two-tailed, and <0.05 were considered 
statistically significant. The distribution of continuous variables was evaluated and 
transformations were conducted for nonparametric variables. Cox proportional hazards 
models were used to estimate hazard ratios (HRs and 95% confidence intervals for mortality 
in each quartile, compared with the lowest quartile as reference for urine ACR. For testing 
linear risk trends, we used the quartile rank as a continuous variable in the regression 
models. We checked the proportional hazards assumption by examining graphs of estimated 
log (-log) survival. The models were initially adjusted for age, sex, center, year of screening 
exam, smoking status, alcohol intake, regular exercise, education level (model 1). In model 
2: the models were further adjusted for BMI, hypertension, diabetes and history of CVD. 
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Associations were examined between urine ACR quartiles and all cause and CVD mortality 
in clinically relevant sub-groups. 
For incident T2DM, models included: adjustment for age, sex, center, year of screening 
exam, smoking status, alcohol intake, regular exercise, education level (Model 1); Model 1 
plus adjustment for FPG, family history of diabetes and BMI (Model 2). Model 3 includes 
adjustment for the same factors as Model 2 plus adjustment for eGFR. For incident 
hypertension, Model 1 included adjustment for age, sex, center, year of screening exam, 
smoking status, alcohol intake, regular exercise, education level (Model 1); Model 1 plus 
adjustment for SBP and BMI (Model 2). Model 3 includes adjustment for the same factors as 



































































The baseline characteristics of the cohort according to death, CVD death, incident 
hypertension and incident diabetes at follow up are shown in Table 1. There were 349 
deaths during follow up and blood pressure and the proportion of subjects with hypertension 
and diabetes was higher in subjects who died during follow up. UACR was increased at 
baseline in subjects who died during follow up  To investigate associations between 
increasing UACR and risk factors for all cause and cardiovascular mortality, we examined 
the trends across UACR quartiles and risk factors for all cause and cardiovascular mortality. 
Table 2 shows the baseline characteristics of the cohort according to baseline UACR 
quartiles. Quartiles of UACR were for quartile 1: <3.4 mg/g(0.38 mg/mmol); quartile 2: 3.4-
4.7 mg/g(0.38-0.53 mg/mmol); quartile 3: 4.7 -7.4 mg/g(0.53-0.84 mg/mmol) and for the 
highest quartile ≥7.4 mg/g(0.84mg/mmol). There was a significant increase in the proportion 
of people with diabetes, obesity and hypertension across UACR quartiles. There were 
remarkably similar eGFR values across UACR quartiles, with eGFR varying by only 0.4 
ml/min across UACR quartiles. 
 
We investigated associations between baseline UACR quartiles and all cause and CVD 
mortality. Table 3 shows the HRs for the associations between UACR quartiles and all cause 
and CVD mortality. The fully adjusted models showed a significant trend with increasing 
UACR quartiles a d CVD mortality. Adjustment for eGFR in these models had an impact on 
the strength of the association between UACR and all cause mortality. Before adjustment for 
eGFR, there was a significant trend for the association between UACR and all cause 
mortality, p=0.036; whereas after adjustment for eGFR, there was a decrease in the strength 
of the association between UACR and all cause mortality, p=0.078.  
As can be seen for CVD mortality with each increasing quartile of UACR there was an 
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Quartile 3, HR=2.05; Quartile 4, HR=3.38, p value for the trend across increasing quartiles 
p=0.029). 
 
Next we tested associations between baseline UACR and CVD mortality (Figure 1) and 
baseline UACR and all cause mortality (Figure 2) in clinically relevant sub groups. These 
analyses investigations trends across UACR quartiles and interaction between sub group 
and UACR. For CVD mortality there were significant interactions with age and vigorous 
exercise. For all cause mortality no significant interactions with UACR were noted. 
 
We investigated associations between baseline UACR and both incident hypertension and 
incident diabetes at follow up. In the fully adjusted models there was a significant HR for the 
association between UACR and incident hypertension [highest UACR quartile HR 1.95 (95% 
CI 1.51,2.53) and the p value for the trend across UACR quartiles was p<0.001] (Table 4). In 
contrast, in the fully adjusted models there was a non significant HR for the association 
between UACR and incident diabetes [highest UACR quartile HR 1.15 (95% CI 0.79,1.66) 




































































We show for the first time that UACR below 30mg/g is associated with increased risk of 
incident hypertension and CVD mortality over 10 years of follow up. Our results show there 
was a linear trend for increased risk of incident hypertension and CVD mortality, with very 
low grade albuminuria defined by UACR, and these trends were independent of eGFR levels. 
eGFR only varied by 0.4 ml/min across UACR quartiles and the HRs for the associations 
between UACR and each outcome were not materially affected by adjustment for eGFR in 
the regression models. The associations we observed are in a healthy, young occupational 
cohort without overt renal disease and although many of the risk factors for type 2 diabetes 
and hypertension are shared, it is important to note that there was no significant association 
between baseline UACR and incident diabetes. Importantly, our data adds uniquely to 
current knowledge, since we show that very low levels of albuminuria  are a risk factor for 
both incident hypertension and also CVD mortality and the linear increase in risk, from zero 
to <30mg/g therefore suggests strongly that any albuminuria is a risk factor for vascular 
disease. Whether hypertension represents the intermediary causal link between UACR and 
increased CVD mortality is uncertain, as it is not possible to prove a causal link from this 
cohort study.  
 
In general, urinary albumin excretion is classified as: normoalbuminuria (<30 mg per day or 
UACR < 30 mg/g), microalbuminuria (30–300 mg per day or UACR 30–300 mg/g) and 
macroalbuminuria (>300 mg per day or UACR > 300 mg/g). Thus, it is important to note that 
all individuals included in this study in all quartiles of UACR would be classified has having 
normoalbuminuria. Consequently, our results strongly suggest that even within the normal 
range of urinary albumin excretion, an increase in UACR is associated with CVD mortality 
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Low levels of eGFR are associated with renal impairment and albuminuria, but our results 
show clearly that the association between low grade albuminuria and mortality outcomes 
and incident hypertension were independent of eGFR levels. A previous cohort study 
undertaken in North and South America and Europe which followed individuals aged ≥55 
years for a median 4.5 years showed that any degree of albuminuria was a risk factor for CV 
events.11 Another Multicenter cohort study involving patients with hypertension and left 
ventricular hypertrophy also showed an association between UACR and increased 
cardiovascular morbidity and mortality with no threshold of UACR contributing to increased 
risk.12 These results are in keeping with our results and with our previous study in which we 
showed an association between different cardiovascular risk factors and low grade 
albuminuria.13 However, the baseline characteristics of subjects in these studies were very 
different from the baseline characteristics of subjects in the present study. In these previous 
studies, there was inclusion of subjects with recognized cardiovascular risk factors at 
baseline, such as diabetes,11 hypertension with left ventricular hypertrophy,12 and coronary 
artery disease.13 Furthermore, baseline UACR was notably higher in these previous studies 
than in the presented data. Consequ ntly, the presented data are novel and this is the first 
study to show that UACR below 30mg/g, is associated with increased risk of CVD mortality. 
   
Why is low grade albuminuria, UACR below 30mg/g, associated with increased CVD 
mortality and incident hypertension? Increased albumin excretion is the net result of 
glomerular filtration and tubular resorption and it is suggested that in normal physiological 
conditions there is little filtration. When irreversible increases in albumin excretion occur it is 
assumed that there is increased glomerular hydraulic pressure, increased glomerular 
filtration coefficient, change in size and charge selectivity of the glomerular membrane.7 The 
mechanisms linking increased albuminuria and cardiovascular mortality are uncertain, but it 
is likely that increased urinary albumin excretion reflects widespread vascular endothelial cell 
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atherogenic lipoproteins within the subendothelial cell space.15 Thus, increased albuminuria 
might reflect glomerular and/or systemic vascular endothelial dysfunction that precedes 
development of hypertension in humans.16 In previous cross-sectional studies, increased 
urinary albumin excretion was associated with increased blood pressure in subjects with 
hypertension17, 18 and in the general population,19 suggesting that the increased level of 
urinary albumin excretion in the present study could be in part due to an increase in blood 
pressure below levels to diagnose hypertension. 
Although CVD and diabetes share many risk factors in common (the common soil 
hypothesis8) and as discussed above microalbuminuria occurs in people with diabetes and 
CVD, our data suggests a dis-connect between diabetes and CVD, since in contrast to CVD 
mortality and hypertension, low grade albuminuria was not significantly associated with any 
marked increase in incident diabetes. Thus, we suggest that these data lend credence to the 
notion that microalbuminuria/albuminuria occurs as a co sequence of vascular dysfunction 
in diabetes, rather than albuminuria/vascula  dysfunction being a causal factor in the 
pathogenesis of diabetes.  
 
Our study does have some limitations that should be discussed. UACR measurement was 
only available from a single measurement and since UACR can vary from day to day this will 
result in imprecision in the UACR measurement. Moreover, although the absolute variability 
in ACR decreases with the magnitude of albuminuria, on the other hand a percentage of 
baseline ACR variability increases.20 However, there is a considerable amount of evidence 
showing that a simple single-voided test is reliable and useful in screening for disease and 
follow-up of patients, and this methodology avoids the problems associated with a 24-hour 
urine collection.20-24 Despite the potential imprecision associated with a single voided 
measurement of UACR, we have studied a large number of subjects in this cohort and any 
imprecision in the measurement of UACR would bias results towards the null. Although our 
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underestimated since it is known that the MDRD Study equation underestimates measured 
GFR when GFR is ≥60 ml/min/1.73m2 in healthy individuals.25 Furthermore, it is possible 
that development of diabetes or hypertension during follow up has influenced our results 
although our study design has limited this possibility by exclusion of these subjects at 
baseline. Although the follow up time was a little different for studying the associations 
between baseline UACR and incident diabetes and incident hypertension, compared to 
studying associations with mortality outcomes, it should be noted that there were similar 
associations between baseline UACR and incident hypertension and CVD mortality, in 
contrast to the (lack of an) association between baseline UACR and incident diabetes. Thus, 
it seems unlikely that the shorter period of follow up for incident diabetes has influenced our 
results. 
In summary, our results show for the first time that in a young predominantly healthy 
occupational cohort that UACR below 30mg/g, is an independ nt risk factor for incident 
hypertension and CVD mortality during a maximum of 11 years of follow up. In contrast, low 
grade albuminuria was not a risk factor for incident diabetes during the same period of follow 
up. Whether hypertension represents the intermediary causal link between UACR and 
increased CVD mortality is uncertain, as it is not possible to prove a causal link from this 
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Figure 1  
Risk of CVD mortality according to sub-group and quartiles of ACR concentration 
Figure 2 
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Total Number 37091 37091 37091  37091 37091  9102 9102  10930 10930  
Number of event 37,091 36,742 349  37,041 50  8,139 963  10,419 511  
N (%) Men 19,688(53.1) 19,437(52.9) 251(71.9)  19,652(53.1) 36(72.0)  4,187(51.4) 665(69.1)  5,768(55.4) 360(70.5)  
Age (years) 45.8(11.9) 45.7(11.9) 57.2(12.0) <0.001 45.8(11.9) 58.9(12.6) <0.001 42.1(10.1) 47.6(10.2) <0.001 43.7(10.6) 49.6(9.6) <0.001 
BMI (kg/m2) 23.6(3.2) 23.6(3.2) 23.9(3.3) 0.109 23.6(3.2) 24.0(3.6) 0.402 23.0(2.9) 24.6(2.9) <0.001 23.4(3.0) 25.3(2.8) <0.001 
Systolic BP (mmHg) 115.9(14.9) 115.9(14.8) 123.6(16.8) <0.001 115.9(14.8) 127.4(18.8) <0.001 110.4(10.8) 119.1(9.9) <0.001 114.7(14.0) 121.8(14.4) <0.001 
Diastolic BP (mmHg) 74.9(9.9) 74.9(9.9) 78.5(9.8) <0.001 74.9(9.9) 81.2(10.7) <0.001 71.6(7.8) 77.5(6.7) <0.001 74.5(9.7) 79.2(9.4) <0.001 
Higher education (%)* 11,046(55.7) 10,964(56.0) 82(35.2) <0.001 11,034(55.8) 12(35.3) 0.016 2,927(70.4) 316(55.2) <0.001 3,710(67.3) 134(47.9) <0.001 
Regular exercise (%)† 7,183(19.4) 7,122(19.4) 61(17.5) 0.370 7,177(19.4) 6(12.0) 0.187 1,475(18.1) 213(22.1) 0.003 1,988(19.1) 114(22.3) 0.071 
Current smoker (%) 9,774(26.4) 9,654(26.3) 120(34.4) 0.001 9,758(26.3) 16(32.0) 0.364 2,111(25.9) 289(30.0) 0.007 2,674(25.7) 163(31.9) 0.002 
Alcohol intake ≥ 7,542(20.3) 7,457(20.3) 85(24.4) 0.061 7,533(20.3) 9(18.0) 0.682 1,459(17.9) 272(28.3) <0.001 2,076(19.9) 170(33.3) <0.001 
Fatty liver (%) 10,882(29.3) 10,784(29.4) 98(28.1) 0.603 10,865(29.3) 17(34.0) 0.469 1,960(24.1) 378(39.3) <0.001 2,809(27.0) 299(58.5) <0.001 
Obesity (%) 11,691(31.5) 11,569(31.5) 122(35.0) 0.165 11,674(31.5) 17(34.0) 0.706 1,976(24.3) 407(42.3) <0.001 3,064(29.4) 271(53.0) <0.001 
Hypertension (%) 8,740(23.6) 8,594(23.5) 146(41.8) <0.001 8,714(23.6) 26(52.0) <0.001    - - - 
Diabetes (%) 2,314(6.2) 2,254(6.1) 60(17.2) <0.001 2,305(6.2) 9(18.0) 0.001 - - - 1,323(12.7) 1,443(23.5) <0.001 
Hx of CVD (%) 3,016(8.1) 2,978(8.1) 38(10.9) 0.058 37,041(8.1) 9(18.0) 0.011 - - - - - - 
Insulin (μIU/ml) 8.01(6.27-10.26) 8.01(6.27-10.26) 8.23(6.63-10.68) 0.001 8.01(6.27-10.26) 8.32(6.58-10.36) 0.411 4.69(3.1-6.73) 5.5(4.01-8.03) 0.002 4.8(3.17-6.85) 6.15(4.1-8.71) 0.007 
Glucose (mg/dl) 96.4(17.8) 96.3(17.7) 104.0(27.3) <0.001 96.4(17.8) 101.8(22.6) 0.033 93.4(13.6) 99.1(18.6) <0.001 92.6(8.7) 105.5(10.9) <0.001 
Total cholesterol (mg/dl) 195.9(35.2) 195.9(35.2) 193.5(37.9) 0.202 195.9(35.2) 200.2(26.7) 0.383 193.2(33.7) 202.1(35.2) <0.001 195.2(34.1) 207.3(35.7) <0.001 
LDL-C (mg/dl) 115.6(31.3) 115.6(31.3) 111.0(32.0) 0.006 115.6(31.3) 119.5(22.9) 0.380 113.2(30.0) 120.5(31.7) <0.001 114.8(30.4) 122.7(32.8) <0.001 































































































R2   
 
Triglycerides (mg/dl) 103(72-154) 103(72-154) 114(82-162) <0.001 103(72-154) 117(82-167) 0.215 94(67-140) 122(86-177) <0.001 100(70-148) 152(104-218) <0.001 
HOMA IR 1.87(1.40-2.48) 1.86(1.40-2.48) 2.05(1.55-2.69) <0.001 1.86(1.40-2.48) 2.05(1.60-2.48) 0.175 1.81(1.36-2.34) 2.04(1.60-2.70) <0.001 1.84(1.40-2.37) 2.42(1.88-3.17) <0.001 
eGFR (ml/min) 81.6(14.4) 81.7(14.4) 76.6(13.0) <0.001 81.6(14.4) 72.9(12.9) <0.001 83.5(14.4) 78.5(12.0) <0.001 82.1(14.2) 77.5(12.9) <0.001 
*≥college graduate  † ≥ 3 time per week 
SI conversion factors (multiply the conversion factor to obtain SI unit): insulin, 6.945 (pmol/L); glucose,0.0555(mmol/L); total 

































































































Table 2: Baseline characteristics of study subjects by UACR quartile 
Characteristics Overall 
ACR quartiles 
P for trend Q1  
(<3.4mg/g) 






N= 37,091  9,273 9,274 9,272 9,272  
Age (years) 45.8 (11.9) 42.6 (10.7) 44.5 (11.3) 46.6 (11.9) 49.5 (12.5) <0.001 
BMI (kg/m2) 23.6 (3.2) 23.7 (2.9) 23.3 (3.0) 23.4 (3.2) 24.0 (3.5) <0.001 
Systolic BP (mmHg) 115.9 (14.9) 113.5 (12.5) 113.7 (13.7) 115.8 (14.8) 120.7 (16.9) <0.001 
Diastolic BP (mmHg) 74.9 (9.9) 73.8 (9.0) 73.7 (9.5) 74.8 (9.9) 77.5 (10.7) <0.001 
Higher education (%)* 11,046(55.7) 3,138(68.3) 2,893(58.9) 2,651(52.7) 2,364(44.8) <0.001 
Regular exercise (%)† 7,183(19.4) 1,796(19.4) 1,798(19.4) 1,799(19.4) 1,790(19.3) 0.925 
Current smoker (%) 9,774(26.4) 3,566(38.5) 2,448(26.4) 1,914(20.6) 1,846(19.9) <0.001 
Alcohol intake ≥ 20g/day (%) 7,542(20.3) 2,447(26.4) 1,865(20.1) 1,535(16.6) 1,695(18.3) <0.001 
Obesity (%) 11,691(31.5) 2,881(31.1) 2,611(28.2) 2,732(29.5) 3,467(37.4) <0.001 
Hypertension (%) 8,740(23.6) 1,363(14.8) 1,708(18.5) 2,180(23.6) 3,489(37.7) <0.001 
Diabetes (%) 2,314(6.2) 246(2.7) 378(4.08) 551(5.9) 1,139(12.3) <0.001 
Hx of CVD (%) 3,016(8.1) 593(6.4) 732(7.9) 810(8.7) 881(9.5) <0.001 

































































































Glucose (mg/dl) 96.4 (17.8) 93.9 (11.6) 94.4 (14.6) 96.0 (16.8) 101.2 (24.6) <0.001 
Total cholesterol (mg/dl) 195.9 (35.2) 193.6 (33.5) 194.1 (34.2) 196.2 (35.4) 199.8 (37.3) <0.001 
LDL-C (mg/dl) 115.6 (31.3) 116.0 (30.1) 114.2 (30.6) 114.8 (31.3) 117.5 (33.0) 0.001 
HDL-C (mg/dl) 55.7 (13.3) 54.3 (12.8) 56.2 (13.3) 56.8 (13.7) 55.6 (13.4) <0.001 
Triglycerides (mg/dl) 103(72-154) 105(75-152) 99(70-146) 99(69-149) 111(76-169) <0.001 
HOMA IR 1.87(1.40-2.48) 1.75(1.29-2.31) 1.84(1.40-2.40) 1.88(1.43-2.49) 2.01(1.48-2.74) <0.001 
eGFR (ml/min) 81.6 (14.4) 81.7 (13.4) 81.6 (14.1) 81.8 (14.6) 81.4 (15.5) 0.309 
*≥college graduate. † ≥ 3 time per week 
SI conversion factors (multiply the conversion factor to obtain SI unit): insulin, 6.945 (pmol/L); glucose,0.0555(mmol/L); total 


















































































































HR (95% CI) 
Multivariate HR*(95% CI)  
Model 1 Model 2 Model 3 Model 4 
All cause mortality         
Q1 (<3.4mg/g) 42,971.8 63 146.6 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Q2 (3.4-4.7 mg/g) 47,491.7 67 141.1 0.93(0.66-1.32) 0.77(0.49-1.20) 0.76(0.49-1.18) 0.74(0.48-1.15) 0.74(0.47-1.15) 
Q3 (4.7-7.4 mg/g) 47,411.1 89 187.7 1.13(0.81-1.57) 1.05(0.69-1.58) 1.04(0.69-1.56) 0.99(0.66-1.50) 0.98(0.65-1.48) 
Q4 (≥7.4 mg/g) 47,135.7 130 275.8 1.33(0.97-1.83) 1.37(0.93-2.03) 1.33(0.89-1.98) 1.25(0.83-1.86) 1.25(0.84-1.87) 
P for trend    0.025 0.019 0.036 0.078 0.069 
CVD mortality         
Q1 (<3.4mg/g) 42,971.8 7 16.3 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Q2 (3.4-4.7 mg/g) 47,491.7 11 23.2 1.35(0.52-3.51) 1.42(0.34-6.00) 1.40(0.33-5.90) 1.45(0.34-6.15) 1.43(0.94-6.05) 
Q3 (4.7-7.4 mg/g) 47,411.1 10 21.1 1.09(0.41-2.94) 1.97(0.51-7.61) 1.93(0.50-7.50) 2.05(0.53-7.96) 2.03(0.52-7.90) 
Q4 (≥7.4 mg/g) 47,135.7 22 46.7 1.89(0.77-4.61) 3.46(0.97-12.35) 3.14(0.86-11.48) 3.38(0.92-12.39) 3.37(0.92-12.36) 
P for trend    0.163 0.020 0.038 0.029 0.028 

































































































* Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, regular exercise, ed cation level; Model 2: 
model 1 adjustments plus adjustment for BMI, hypertension, diabetes and history of CVD; Model 3: model 2 adjustments plus adjustment for 

































































































Table 4. Risk of incident hypertension according to baseline ACR quartiles 











Multivariate HR*(95% CI)  
Model 1 Model 2 Model 3 Model 4 
N=9,102         
Q1 (<3.4mg/g) 7,171.4 167 23.3 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Q2 (3.4-4.7mg/g) 7,657.3 198 25.9 1.33(1.08-1.64) 1.23(0.93-1.63) 1.17(0.88-1.55) 1.18(0.89-1.56) 1.17(0.89-1.56) 
Q3 (4.7-7.4mg/g) 7,655.3 241 31.5 1.72(1.40-2.11) 1.61(1.23-2.12) 1.46(1.11-1.92) 1.48(1.12-1.94) 1.50(1.14-1.97) 
Q4 (≥7.4 mg/g) 7,134.9 357 50.0 2.54(2.10-3.08) 2.42(1.88-3.13) 1.94(1.50-2.50) 1.95(1.51-2.53) 1.97(1.52-2.55) 
P for trend    <0.001 <0.001 <0.001 <0.001 <0.001 
SI units for ACR : divided by 8.84, mg/mmol 
* Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, regular exercise, education level; Model 2: 

















































































































HR (95% CI) 
Multivariate HR*(95% CI)  
Model 1 Model 2 Model 3 Model 4 
N=10,930         
Q1 (<3.4mg/g) 9,064.2 100 11.0 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Q2 (3.4-4.7mg/g) 9,754.9 106 10.9 1.07(0.81-1.41) 1.01(0.68-1.51) 0.83(0.56-1.25) 0.83(0.55-1.24) 0.84(0.56-1.26) 
Q3 (4.7-7.4mg/g) 9,792.8 130 13.3 1.33(1.02-1.74) 1.52(1.05-2.20) 1.06(0.73-1.55) 1.05(0.72-1.53) 1.03(0.71-1.51) 
Q4 (≥7.4 mg/g) 9,337.3 175 18.7 1.70(1.32-2.20) 1.83(1.28-2.62) 1.16(0.81-1.68) 1.15(0.79-1.66) 1.14(0.78-1.64) 
P for trend    <0.001 <0.001 0.174 0.195 0.240 
SI units for ACR : divided by 8.84, mg/mmol 
* Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, regular exercise, education level; Model 2: 
model 1 plus adjustment for glucose, family history of diabetes and BMI ; Model 3: model 2 plus adjustment for eGFR; Model 4: model 3 























































    

















































No diabetes (n=34,776) 
Current smoker(n=9,774) 
< college graduate(n=8,779) 
Alcohol < 20g/day(n=29,549) 
eGFR % < 60ml/min (n=1,135) 
Non or ever smoker(n=27,317) 
eGFR % ≥ 90ml/min (n=8,767) 
Alcohol  ≥ 20g/day (n=7,542) 
Age  ≥ 50 years (n=13,601) 
 ≥ college graduate(n=11,046) 
Vigorous exercise < 3 time/week 
BMI < 25 kg/m2 (n=25,399) 
Fatty liver (n=10,882) 
No Fatty liver (n=26,205) 
Homa < 75%ile (n=28,315) 
Men (n=19,688) 




















































































































































































Alcohol ≥ 20g/day  
Current smoker 
Age <50 years 
No Fatty liver 
Alcohol < 20g/day 
≥ college graduate  
Age ≥ 50 years 
Women 
Vigorous exercise < 3 time/week 
Non or ever smoker 
eGFR % ≥ 90ml/min 
< college graduate 
Vigorous exercise ≥ 3 time/week 







eGFR % ≥ 60ml/min 
















Homa < 75%ile 
diabetes 
No diabetes 
BMI < 25 kg/m2 




BMI ≥ 25 kg/m2 
0.88 (0.30-2.57) 
1.06 (0.40-2.84) 
1.56 (0.65-3.75) 
1.06 (0.68-1.67) 
0.50(0.14-1.76) 
1.05(0.65-1.70) 
0.85 (0.37-1.95) 
1.12(0.71-1.74) 
0.62 (0.30-1.29) 
1.37 (0.86-2.20) 
1.50(0.71-3.16) 
1.52(0.97-2.38) 
1.44 (0.68-3.05) 
0.69 (0.42-1.15) 
1.18 (0.62-2.22) 
1.35 (0.54-3.35) 
1.38(0.63-3.03) 
1.54 (0.82-2.88) 
1.00 (0.59-1.71) 
0.73 (0.43-1.24) 
0.95 (0.49-1.85) 
1.32(0.84-2.06) 
0.54(0.30-0.95) 
0.33(0.10-1.03) 
0.70 (0.43-1.15) 
1.40 (0.83-2.34) 
0.63(0.24-1.63) 
0.84 (0.47-1.48) 
1.27 (0.76-2.13) 
0.80(0.50-1.29) 
1.05(0.42-2.63) 
1.25(0.80-1.94) 
0.63 (0.35-1.15) 
0.99 (0.62-1.58) 
1.41(0.62-3.18) 
0.90 (0.55-1.47) 
1.09 (0.50-2.38) 
1.07 (0.39-2.93) 
1.06 (0.55-2.03) 
1.40 (0.91-2.17) 
1.14(0.72-1.80) 
1.35 (0.85-2.13) 
0.50(0.14-1.73) 
0.95 (0.55-1.63) 
1.39(0.54-3.63) 
1.13 (0.59-2.17) 
0.80 (0.28-2.28) 
0.88(0.54-1.42) 
0.77(0.49-1.20) 
3.91(0.41-36.82) 
3.48(0.38-32.13) 
0.77(0.49-1.20) 
1.26(0.83-1.90) 
0.70(0.42-1.17) 
1.55(0.98-2.43) 
1.07(0.43-2.68) 
1.03(0.61-1.76) 
0.18 (0.02-1.78) 
0.98 (0.63-1.52) 
1.06(0.66-1.68) 
0.83 (0.53-1.32) 
0.86(0.50-1.48) 
1.75(1.05-2.90) 
1.56 (0.41-5.89) 
1.26 (0.35-4.50) 
0.96(0.37-2.51) 
0.98(0.40-2.38) 
1.38 (0.90-2.11) 
1.01(0.52-1.97) 
0.61(0.28-1.31) 
0.90(0.47-1.73) 
0.081 
0.859 
0.502 
 0.213 
0.484 
0.502 
0.314 
0.310 
0.355 
0.528 
0.240 
0.330 
10,882 
7,542 
9,774 
23,490 
26,205 
29,549 
11,046 
13,601 
17,403 
29,908 
27,317 
8,767 
8,779 
7,183 
28,324 
19,688 
35,956 
1,135 
28,315 
2,314 
34,776 
25,399 
8,773 
11,691 
Variable No. 
